Synthesis and antifungal activity of a ferrocene-fluconazole analogue

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 8, 2000, Pages 839-841

  Biot, Christophe ^a   François, Nadine ^b   MacIejewski, Lucien ^a   Brocard, Jacques ^a   Poulain, Daniel ^b  

^a UNITÉ DE CATALYSE ET DE CHIMIE DU SOLIDE   (France)

^b Faculty of Medicine   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FERROCENE DERIVATIVE; FERROCENE FLUCONAZOLE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; DRUG SYNTHESIS; FUNGUS GROWTH; IC 50; IN VITRO STUDY; NONHUMAN; YEAST;

ANTIFUNGAL AGENTS; CANDIDA; FERROUS COMPOUNDS; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; SPECIES SPECIFICITY;

FUNGI;

EID: 0342313480     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00120-7     Document Type: Article

References (23)

1. Dombrowski K.E., Baldwin W., Sheats J.E. J. Organomet. Chem. 302:1986;281.
2. Yeary R.A. Toxicol. Appl. Pharm. 15:1969;666.
3. For a review about metal complexes for therapy and diagnosis of drug resistance, see: Sharma, V.; Piwnica-Worms, D. Chem. Rev. 1999, 99, 2545.
4. Top, S.; Tang, J.; Vessières, A.; Carrez, D.; Provot, C.; Jaouen, G. J. Chem. Soc., Chem. Comm. 1996, 955.
5. Top S., Dauer B., Vaissermann J., Jaouen G. J. Organomet. Chem. 541:1997;355.
6. Brocard, J.; Lebibi, J.; Maciejewski, L. Brevet France 9505532, 1995.
7. Brocard, J.; Lebibi, J.; Maciejewski, L. Brevet International PCT/FR 96/00721, 1996; Chem. Abs. 1997, 126, 60137E.
8. Biot C., Glorian G., Maciejewski L., Brocard J., Domarle O., Blampain G., Millet P., Georges A.J., Abessolo H., Dive D., Lebibi J. J. Med. Chem. 40:1997;3715.
9. Domarle O., Blampain G., Agnanet H., Nzadiyabi T., Lebibi J., Brocard J., Maciejewski L.A., Biot C., Georges A.J., Millet P. Antimicrob. Agents Chemother. 42:1998;540.
10. For a review about the azoles as antifungal agents, see: Terrell, C. L. Maya Clin. Proc. 1999, 74, 78.
11. Vanden Bossche H., Warnock D.W., Dupont B., Kerridge D., Sen Gupta S., Improvisi L., Marichal P., Odds F.C., Provost F., Ronin O. J. Med. Vet. Mycol. 32:1994;189.
12. Dupont B. Curr. Opin. Infect. Dis. 8:1995;424.
13. Vanden Bossche H., Dromer F., Improvisi L., Lozano-Chire M., Rex J.H., Sanglard D. Med. Mycol. 36:1998;119.
14. Minn Y., Brummer E., Stevens D.A. Mycopathologia. 138:1997;29.
15. Hanzlik R.P., Robert P., Soine W.K. J. Am. Chem. Soc. 180:1978;1290.
16. Further information about new approaches to antifungal chemotherapy: Viviani, M. A.; de Marie, S.; Graybill, J. R.; Yamaguchi, H.; Anaissie, E.; Caillot, D. Med. Mycol. 1998, 36, 194.
17. Rebiere F., Samuel O., Kagan H.B. Tetrahedron Lett. 31:1990;3121.
18. Richardson, K. U.S. Patent 4,404,216, 1983.
19. 6OFe:C, 59.97; H, 4.76; N, 22.22; found:C, 60.01; H, 4.93; N, 22.51.
20. 3OClFe: C, 52.10; H, 4.63; N, 12.16; found: C, 52.32; H, 4.44; N, 12.30.
21. Dannenberg J.J., Levenberg M.K. Tetrahedron. 29:1973;1575.
22. The antifungal activity was determined by liquid-phase turbidimetry using Titertek Multiskan apparatus operating at 620 nm. Dei Cas, E.; Duardin, L.; Ribeiro Pinto, M. E.; Ajana, F.; Fruit, J.; Poulain, D.; Camus, D.; Vernes, A. Mycoses 1991, 34, 167.
23. Ten Candida isolates were used in this study according to their MIC, which was defined as the FCZ concentration leading to 80% growth inhibition. Three C. albicans strains (MIC <1.5 μg/mL), two C. glabrata strains (MIC >48 μg/mL), two C. parapsilosis strains (MIC <12 μg/mL) and three C. krusei strains (MIC >48 μg/mL).